Allergan’s multidose Restasis nabs FDA approval, heads to battle with Shire’s Xiidra

(Allergan)

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a new challenge named Xiidra lies ahead.

The Allergan blockbuster works to reverse low natural tear production, a symptom that might be found among those with chronic dry eye disease--and the newly approved version turns the same formulation of single-vial Restasis, launched in 2003, into a multidose bottle. It also uses a patented unidirectional valve and air filter technology in place of a preservative. The new Restasis bottle uses less plastic than a package of single-use vials and will be available for the same price. 

The product ran into a regulatory setback early this March, as the FDA handed the Dublin drugmaker a complete response letter, asking for additional CMC information.

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

Restasis was pretty comfortable with its monopoly status until Shire decided to enter the game with its dry-eye candidate lifitegrast, which is currently marketed under the brand name Xiidra. Allergan has been counting on the new multidose Restasis to give it a boost against the newcomer. 

It was quite a regulatory journey for Xiidra, too. Last October, the FDA handed the Irish biopharma a complete response letter of its own, saying the company had to provide more clinical work to convince the agency of the drug’s quality. It was almost a year later when Shire finally got what it wished for--an FDA approval for Xiidra for the treatment of both the signs and symptoms of dry eye disease.

Shire has since touted Xiidra as a first-of-its-kind eye drop approved in the U.S., since Restasis is only intended for “tear production,” not dry eye disease, even though the previous is one of the possible symptoms of the latter.

And now, with its new marketing strategies in place accompanying the launch of Xiidra, Shire seems determined to grab a share from Allergan’s blockbuster, despite a later entrance. About two months ago, it allied with actress Jennifer Aniston in promoting its new eye health and disease education campaign called “eyelove,” and even though the campaign does not specifically promote the product, it’s still good publicity for Shire.

On the other hand, Allergan, as a well-established player in the field, has recruited actress Marisa Tomei as spokesperson for Restasis marketing and has been downplaying the threat posed by Shire.

Related Articles:
Shire's new dry-eye approval means it's time for an Allergan showdown
Shire snags eye-drop 'addicted' Jennifer Aniston as new dry eye spokeswoman
Restasis-maker Allergan recruits actress Marisa Tomei to drive dry eye awareness
Allergan's Restasis defense stumbles at FDA as Shire loads up lifitegrast assault

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.